Clinical Trials Logo

Neoplasm Malignant clinical trials

View clinical trials related to Neoplasm Malignant.

Filter by:

NCT ID: NCT01156870 Completed - Neoplasm Malignant Clinical Trials

First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor

Start date: September 8, 2010
Phase: Phase 1
Study type: Interventional

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR566658 Secondary Objectives: - To characterize the safety profile of SAR566658 - To evaluate the pharmacokinetic profile of SAR566658 - To assess the potential immunogenicity of SAR566658 - To assess preliminary antitumor activity - To assess the effect of SAR566658 at recommended dose on CYP3A enzyme activity using midazolam - To assess safety in the alternative schedules of SAR566658 administration

NCT ID: NCT01148615 Completed - Neoplasm Malignant Clinical Trials

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Start date: July 2010
Phase: Phase 1
Study type: Interventional

Primary Objective: - To confirm the dose of aflibercept in western studies by assessing the dose-limiting toxicity (DLT) of intravenous (IV) aflibercept when administered in combination with docetaxel given intravenously every 3 weeks in Chinese patients with solid tumors. Secondary Objectives: - To assess the safety profile of intravenous (IV) aflibercept when administered in combination with docetaxel - To determine the pharmacokinetics of IV aflibercept and docetaxel when administered in combination - To make a preliminary assessment of antitumor effects of the combination of docetaxel plus aflibercept in patients with evaluable disease - To evaluate the immunogenicity of IV aflibercept - To measure endogenous free Vascular Endothelial Growth Factor (VEGF)

NCT ID: NCT01140607 Completed - Neoplasm Malignant Clinical Trials

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

Start date: May 2010
Phase: Phase 1
Study type: Interventional

Primary Objectives: - To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic impairment - To determine the pharmacokinetics (PKs) of Cabazitaxel in patients with varying degrees of hepatic impairment - To correlate PK variables with pharmacodynamic (PD) safety parameters in order to guide prescribers with regard to dosing in this patient population - To assess the effect of cabazitaxel at recommended dose of 25mg/m^2 on CYP3A enzyme activity using midazolam as probe in an additional cohort of cancer patients with normal hepatic function.

NCT ID: NCT00732992 Completed - Neoplasm, Malignant Clinical Trials

A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Start date: August 2008
Phase: Phase 1
Study type: Interventional

This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.